Dyne therapeutics ipo
WebMay 14, 2024 · WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, is presenting new preclinical data from its myotonic dystrophy type 1 (DM1) program … WebMar 20, 2024 · WALTHAM, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. DYN, a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people ...
Dyne therapeutics ipo
Did you know?
WebSep 17, 2024 · Dyne Therapeutics raised $233 million in an initial public offering of 12.3 million shares of its common stock at $19.00 per share. ... 40 percent of the money raised by drug developers in IPOs in 2024. Dyne is developing a broad portfolio of therapeutics for muscle diseases, including programs in the rare genetic wasting diseases myotonic ... WebApr 11, 2024 · Dyne Therapeutics has a 52-week low of $4.30 and a 52-week high of $15.63. Dyne Therapeutics ( NASDAQ:DYN - Get Rating ) last issued its quarterly earnings data on Thursday, March 2nd. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.10.
WebSep 17, 2024 · Waltham, Massachusetts-based Dyne Therapeutics, Inc. priced its upsized initial public offering of 12.253 million shares at $19 versus the estimated price range of $16 and $18, to generate gross ... WebDec 23, 2024 · December 23, 2024 7:16 P.M. After raising $267.7 million in gross proceeds from its September initial public offering, Dyne Therapeutics Inc. signed a lease this month to occupy the entire three ...
WebSep 17, 2024 · Dyne Therapeutics, a preclinical biotech developing oligonucleotide therapies for rare muscular diseases, raised $233 million by offering 12.3 million shares … WebSep 17, 2024 · A muscle disease company, Dyne Therapeutics (DYN) has priced its IPO of 12,251,578 common shares at $19.00/share, for expected gross proceeds of ~$233M.Trading kicks off September 17.The...
WebApr 12, 2024 · Since the IPO on September 17, 2024, Dyne Therapeutics, Inc.'s market cap has decreased from $790.90M to $480.56M, a decrease of -39.24%. That is a compound annual growth rate of -17.66%.
WebSep 21, 2024 · Dyne is developing a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral ... dyamond taylorWebAug 26, 2024 · BioNTech signs UK government pact to deliver cancer therapies to 100k patients by 2024. Jan 6, 2024 12:29pm. dyamond kimble excalibur homes llcWebSep 1, 2024 · Dyne Therapeutics (DYN) aims to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The … crystal palace bowl parkingWebAug 25, 2024 · Dyne Therapeutics, a preclinical biotech developing therapies for muscular diseases, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering. The company is using ... crystal palace bowl seating planWebSep 17, 2024 · CureDuchenne celebrates Dyne Therapeutics’ public offering on the Nasdaq, under the ticker “DYN”. Today’s initial public offering (IPO) will elevate Dyne’s financial position and accelerate Dyne’s lead programs, which includes Duchenne muscular dystrophy. CureDuchenne values companies like Dyne that utilize fundraising tools such … dyamond overstreetWebSep 13, 2024 · Summary. Dyne Therapeutics had filed proposed terms for a $175 million U.S. IPO. The firm is advancing treatments for various … dyamond kimble excalibur homesWebTHE VALUE I BRING Over fifteen years of progressive leadership experience on the strategic and operational sides of research & … crystal palace brass band